GenEdit’s nanoparticle delivery tech attracts Genentech partnership, new funding

2024-01-23
·
交易
基因疗法
A genetic medicine is only as good as its delivery mechanism, GenEdit demonstrated Tuesday, securing its second biotech deal and closing a $24 million series A1 round on the strength of its nanoparticle technology.
Dubbed NanoGalaxy, GenEdit’s platform features thousands of chemically distinct hydrophilic nanoparticles (HNPs) designed to overcome the capacity, targeting, immunogenicity and manufacturing challenges faced by traditional methods of delivering genetic payloads, such as viral vectors.
Solutions to delivery obstacles are top-of-mind for many in the industry. Last year, the majority of investors FirstWord spoke with in the first half listed delivery technologies as one of the key innovations they’re watching for both gene therapies and siRNAs.
“Our hydrophilic nanoparticles have a unique set of attributes that make them an ideal solution for delivering genetic medicines,” GenEdit CEO Kunwoo Lee told FirstWord. “They can be screened and optimised for tissue selectivity; they can carry the widest variety of payloads of any delivery system, including DNA, mRNA, siRNA and protein; they can be dosed multiple times and remain active; and they are simple to manufacture and scale up.”
Genentech makes its bet
The delivery potential of GenEdit’s nanoparticles attracted a collaboration with Roche’s Genentech unit, earning the former $15 million upfront.
The partners will use NanoGalaxy to discover and develop HNPs to deliver Genentech’s nucleic acid-based medicines for autoimmune diseases.
Andrew Chan, Genentech’s SVP of research biology, told FirstWord, “This collaboration will complement and leverage Genentech's biological, and drug discovery and development capabilities in our pursuit of novel therapies for autoimmune diseases."
Genentech will be responsible for preclinical, clinical, and regulatory activities. GenEdit is eligible for up to $629 million in milestones, plus tiered royalties.
The partnership is GenEdit’s second in as many years. In 2022, the company signed a deal with Sarepta Therapeutics to leverage NanoGalaxy for gene editing therapeutics to treat neuromuscular diseases.
Funding internal programmes
Simultaneously, GenEdit will put its fresh $24 million venture financing towards development of its own pipeline, as well as further work on NanoGalaxy. The company’s preclinical portfolio includes candidates that target the nervous system.
Tuesday’s round brings the company’s total raise to $58 million, Kunwoo said. Existing investors Eli Lilly, Sequoia Capital, Korea Investment Partners, Woori Venture Partners, DAYLI Partners, KB Investment, IMM Investment and TIMEFOLIO Asset Management participated in the round, along with new investors KDB Silicon Valley, Mirae Asset Venture Investment, ACVC, Pathway Partners, LoftyRock Investment, Terra VC, K2 Investment, Dong-A ST, KIMCO and Huons.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
靶点
-
药物
-
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。